Prelude Capital Management’s Moderna MRNA Stock Holding History

Prelude Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,000	Closed	-$517K	–	1971
2022 Q1	$517K	Sell	3,000 -5,900	-66%	-$993K	0.01%	843
2021 Q4	$2.26M	Sell	8,900 -1,500	-14%	-$439K	0.06%	273
2021 Q3	$4M	Buy	10,400 +9,400	+940%	+$3.47M	0.1%	123
2021 Q2	$235K	Buy	+1,000	New	+$179K	0.01%	1322
2020 Q4	–	Sell	-1,200	Closed	-$85K	–	1723
2020 Q3	$85K	Sell	1,200 -1,000	-45%	-$69.7K	﹤0.01%	965
2020 Q2	$141K	Buy	2,200 +1,500	+214%	+$82.1K	0.01%	840
2020 Q1	$21K	Buy	+700	New	+$16.1K	﹤0.01%	978

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's MRNA Position: Q1 2026 in Review

Prelude Capital Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 7,095 shares — an estimated $209K sold.

Prelude Capital Management first reported a position in MRNA in Q4 2018 and held it in 7 quarters. The position peaked at $1.03M in Q4 2020. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Prelude Capital Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 7,095 Moderna shares in Q1 2026, an estimated $209K.
Prelude Capital Management first reported a position in Moderna in Q4 2018 and held it in 7 quarters.
Prelude Capital Management's Moderna position peaked at $1.03M in Q4 2020.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.